Antisense oligonucleotides - The way forward

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 2, 1999, Pages 142-146

  Wahlestedt, Claes ^a   Good, Liam ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; FOMIVIRSEN; G 1128; GENE EXPRESSION MODULATOR 132; GENE EXPRESSION MODULATOR 92; GPI 2A; INX 3001; ISIS 13312; ISIS 2503; ISIS 3521; OBLIMERSEN; STEALTHVECTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RESEARCH; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NONHUMAN;

EID: 0032945649     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Taylor RW, Chinnery PF, Tumbull DM, Ughtowlers RN: Selective inhibition of mutant human mitochrondrial DNA replication in vitro by peptide nucleic acids. Nat Gent (1997) 15(2):212-215.
2. Majumdar A, Khortin A, Dyatkina N, Lin FL, Powell J, Liu J, Fei Z, Khripine Y, Watanabe KA, George J, Glazer PM, Seidman MM: Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat Genet (1998) 20(2):212-214.
3. Mitsuhashi M: Strategy for designing specific antisense oligonucleotide sequences. J Gastroenterol (1997) 32(2):282-287.
4. Testa SM, Gryaznov SM, Turner DH: Antisense binding enhanced by tertiary interactions: binding of phosphorothioate and N3'-P5f phosphoramidate hexanucleotides to the catalytic core of a group I ribozyme from the mammalian pathogen Pneumocystis carinii. Biochemistry (1998) 37(26):9379-9385. Results show that RNA tertiary interactions can aid in stabilizing binding of short oligonucleotides.
5. Crooke ST: Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev (1998) 8(2):133-134.
6. Ho SP, Bao Y, Lesher T. Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol (1998) 16(1):59-63. Introduces an in vitro method for identifying mRNA sites that are susceptible targets for oligonucleotide binding and subsequent RNase H cleavage.
7. Müner N, Mir KU, Southern EM: Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol (1997) 15(6):537-541. Demonstrates the use of array technology to aid in the selection of antisense oligonucleotides.
8. Branch AD: A good antisense molecule is hard to find. Trends Biochem Sc/(1998) 23(2):45-50. Reviews the difficulties and uncertainties faced in the antisense field.
9. White S, Szewczyk JW, Turner JM. Baird EE, Dervan PB: Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature (1998) 391(6666):468-471. Describes recent progress in developing small molecular weight polyamides for sequence specific recognition of double stranded DNA.
10. Flanagan WM, Wagner RW, Grant D, Lin KY, Matteucci MD: Cellular penetration and antisense activity by a phenoxazine-substituted hepanucleotide. Nat Biotechnol (1999)17(1):48-52.
11. Nielsen PE, Egholm M, Berg RH, Buchardt O: Sequenceselective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science (1991) 254(5037):1497-1500. Describes a full backbone replacement DNA mimic which has shown improved stability properties and potential as an antisense agent.
12. Agrawal S, Zhao Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev (1998) 8(2):135-139.
13. Ho SP, Livanov V, Zhang W, U JH, Lesher T: Modification of pnosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. Molec Brain Res (1998) 62(1):1-11.
14. Egli M: Conformations! preorganization, hydration, and nucleic acid duplex stability. Antisense Nucleic Acid Drug Dev (1998) 8(2):123-128.
15. Herschlag D: Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo-, more isn't always better. Proc NatlAcad Sci USA (1991 ) 88(16):6921 -6925.
16. Wagner RW, Matteucci MD. Grant D, Huang T, Froehler BC: Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol (1996) 14(7):840844. Results show that short oligonucleotides can provide useful selectivity.
17. Wahlestedt C: Antisense oligonucleotide strategies in neuropharmacology. Trends PharmacolSci (1994) 15(2):42-46.
18. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M: Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science (1993) 259(5094):528-531. The first example that antisense oligonucleotides, even if unmodified, can be used to target mRNAs in the living mammalian brain. The approach was subsequently taken by a large number of investigators.
19. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med (1996) 2(6):668-675. Results show extensive mismatch evidence for sequence specific effects in vivo; in vitro results from an mRNA scan for susceptible target sites are provided.
20. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitises human melanoma in SCID mice. War Med (1998) 4(2):232-234.
21. Nyce JW, Metzger WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385(6618):721-725. Effective antisense therapy for lung tissue using aerosol delivery. Demonstrates that lung tissue is an accessible target for antisense oligonucleotides.
22. Suzuki J, Isobe M, Morishila R, Aoki M, Horie S, Okubo Y, Kaneda Y, Sawa Y, Matsuda H, Ogihara T, Sekiguchi M: Prevention of graft coronary arteriosclerosis by arttisense cdk2 kinase oligonucleotide. Nat Med(1997) 3(8):900-903.
23. Tondelli L, Ricca A, Laus M, Lelli M Citro G: Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucl Acid Res (1998)26(23):5425-5431.
24. Bachmann AS, Surovoy A, Jung G, Moelling K: Integrin receptortargeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. J Mol Med (1998) 76(2): 126-132. Results show efficient receptor-mediated uptake of antisense oligonucleotides.
25. Derossi D, Chassaing G, Prochiantz A: Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol (1998)8(2):84-87.
26. Pooga M, Hallbrink M, Zorko M, Langel U: Cell penetration by transportas FASEB J(1998) 12(1):67-77.
27. Rojas M, Donahue JP, Tan Z, Un YZ: Genetic engineering of proteins with cell membrane permeability. Nat Biotechnol (1998)16(4):370-375. Results show the potential for oligonucleotide transport using carrier peptides.
28. Montgomery MK, Rre A: Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet (1998) 14(7):255-258.
29. DeMoor JM, Vincent MD, Collins OM, Koropatnick J: Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription. Exp Cell Res (1998) 243(1 ):11 -21.
30. Delihas N, Rokita SE, Zheng P: Natural antisense RNA/target RNA interactions: possible models for antisense oligo nucleotide drug design. Nat Biotechnol ( 1997) 15(8):751-753.
31. Malmgren C, Wagner EGH, Ehresmann C, Ehresmann B, Romby P: Antisense RNA control of plasmid R1 replication. The dominant product of the antisense RNA-mRNA binding is not a full RNA duplex. J Biol Chem (1997) 272(19):12508-12512. An example of the surprising secondary structures involved in natural ant'sense mechanisms.
32. Cucco C, Calabretta B: In vitro and In vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdrl antisense oligodeoxynucleotides. Cancer Res (1996) 56(19):4332-4337. An example of research showing that mdrl can be inhibited using antisense oligonucleotides.
33. Good L, Nielsen PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol (1998) 16(4):355-358. Results demonstrate gene and sequence specific antisense in Escherichia coli using target site mutation/compensation experiments to prove mechanism.
34. Fraser G, Wahlestedt C: Applications of antisense technology to both basic and clinical research. Exp Opin Invest Drugs (1995)4(7):637-646. Outlines experimental guidelines for antisense studies.
35. Crooke ST: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev(1996) 6(2):145-147. Outlines guidelines for antisense studies and encourages publication of non-antisense effects.
36. Kang SH, Cho MJ, Kole R: Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development B/octeOTSfry(1998) 37(18):6235-6239. Results show increased gene expression associated with antisense inhibition of a regulatory gene. Provides a functional expression system that may have advantages as an assay for comparative experiments in antisense design.